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Edited by Hans-Dieter KlenkAbstract Amino acids N137 and P140 in the p51 subunit of
HIV-1 reverse transcriptase (RT) are part of the b7–b8-loop that
contributes to the formation of the base of the non-nucleoside RT
inhibitor (NNRTI)-binding pocket and makes up a substantial
part of the dimerization interface. Amino acid P95 in p66 also
markedly contributes to the dimerization binding energy. Nine
RT mutants at amino acid 137 were constructed bearing the
mutations Y, K, T, D, A, Q, S, H or E. The prolines at amino
acid positions 95 and 140 were replaced by alanine in separate
enzymes. We found that all mutant RT enzymes showed a dra-
matically decreased RNA-dependent DNA polymerase activity.
None of the mutant RT enzymes showed marked resistance
against any of the clinically used NNRTIs but they surprisingly
lost signiﬁcant sensitivity for NRTIs such as ddGTP. The dena-
turation analyses of the mutant RTs by urea are suggestive for a
relevant role of N137 in the stability of the RT heterodimer and
support the view that the b7–b8 loop in p51 is a hot spot for RT
dimerization and instrumental for eﬃcient polymerase catalytic
activity. Consequently, N137 and P140 in p51 and P95 in p66
should be attractive targets in the design of new structural clas-
ses of RT inhibitors aimed at compromising the optimal interac-
tion of the b7–b8 loop in p51 at the p66/p51 dimerization
interface.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the treatment of human immunodeﬁciency virus type 1
(HIV-1) infections an important number of clinically used
drugs interfere with the viral reverse transcriptase (RT).
To date, three major categories of RT inhibitors can be distin-
guished: (i) 2 0,3 0-dideoxynucleoside analogs designated nucleo-
side RT inhibitors (NRTIs), (ii) acyclic nucleoside phosphonate
analogs designated nucleotide RT inhibitors (NtRTIs), and*Corresponding author. Fax: +32 16 337340.
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doi:10.1016/j.febslet.2005.02.077(iii) non-nucleoside RT inhibitors (NNRTIs) [1,2]. Despite
the diversity of available compounds, HIV variants resistant
to these classes of RT-directed drugs have become increasingly
prevalent in drug-experienced patients. Resistance towards
NNRTIs is primarily associated with mutations of the amino
acids lining the lipophilic NNRTI binding pocket [3,4].
Residues of major importance in the RT structure are often
very highly conserved. Previous studies have revealed that
mutations of conserved amino acids such as W229 [5], Y318
[6] or W401 [7] of HIV-1 RT result in a severe decrease of
the catalytic activity of the enzyme. Interestingly, the W229
and Y318 mutations did not result in a markedly altered sen-
sitivity of the RT to most NNRTIs. Therefore, it would be un-
likely that treatment of HIV-1 infected cells with NNRTIs
targeting these conserved amino acids would result in selection
of resistance mutations at these amino acid positions [5,6].
The catalytic activity of the RT is solely observed with the
(hetero)dimeric form of the enzyme [8]. Thus, compounds that
interfere with the p66/p51 interface may be potentially selective
dimerization inhibitors of RT [9]. An important region at the
p66/p51 interface is the b7–b8-loop in p51 comprising amino
acids from P133 to P140 (PSINNETP) that ﬁts into a
groove-like structure made up by part of the template/primer
binding region in the p66 subunit [10,11]. The tip of this loop
also contributes to the formation of the ﬂoor of the NNRTI
binding pocket. The amino acids of this loop in p51 that make
contact with the p66 subunit (including P95) are I135, N136,
N137, E138 and P140 [12]. The importance of this loop for
structural support and polymerase function of the heterodi-
meric RT was studied by either deletion, or by alanine substi-
tution of amino acids N136, N137, E138 and T139 [10]. In our
study, we introduced nine diﬀerent amino acids (Y, K, T, D, A,
Q, S, H and E) at the highly conserved amino acid position
N137 by site-directed mutagenesis. In addition, we replaced
two prolines by an alanine (P95 in p66 and P140 in p51) in
two separate RT enzymes. These amino acids (i) are highly
conserved among all lentiviruses, (ii) make up an important
part of the dimerization interface [10–12], (iii) contribute to
the formation of the bottom of the NNRTI pocket [11,12],
and (iv) have not yet been reported as susceptible to mutationblished by Elsevier B.V. All rights reserved.
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in cell culture. Given these important characteristics, we inves-
tigated whether these amino acids may act as potential tar-
gets for the design of novel NNRTI or p66/p51 dimerization
inhibitors.
We found that all the mutant enzymes studied markedly lost
catalytic activity but kept high sensitivity to the inhibitory ef-
fect of NNRTIs. Therefore, we conclude that amino acid
N137, together with P95 and P140, should be considered as
target amino acids in the design of novel NNRTIs or dimeriza-
tion inhibitors with the aim to obtain a more favorable drug
resistance proﬁle than that of existing HIV-1 RT inhibitors.2. Materials and methods
2.1. Compounds
[2 0,5 0-Bis-O-(tert-butyldimethylsilyl)-b-D-ribofuranosyl]-3 0-spiro-
500- (400-amino-100,200-oxathiole-200, 200-dioxide) derivatives of N3-methyl-
thymine (TSAO-m3T) and thymine (TSAO-T) were synthesized as
previously described [13]. Nevirapine (BI-RG-587; dipyridodiazepi-
none) was obtained from Boehringer Ingelheim (Ridgeﬁeld, CT). Del-
avirdine [bis(heteroaryl)piperazine (BHAP)] (U-90152) and efavirenz
(DMP-266) were provided by Dr. R. Kirch (at that time at Hoechst
AG, Frankfurt, Germany) and Dr. J.-P. Kleim (currently at Glaxo-
SmithKline, Stevenage, UK). The thiocarboxanilide derivative UC-
781 was obtained from W.G. Brouwer (Middlebury, CT, and Guelph,
Ont., Canada). The quinoxaline GW420867X was provided by
Dr. J.-P. Kleim (GlaxoSmithKline, Stevenage, UK). 2 0,3 0-Dideoxygu-
anosine-50-triphosphate (ddGTP), 2 0,3 0-didehydro-20,3 0-dideoxythymi-
dine-50-triphosphate (d4TTP) and phosphonoformic acid (PFA,
foscarnet) were obtained from Sigma Chemical Ltd. (St. Louis,
MO). (+)-Calanolide A was delivered by Sarawak MediChem Pharma-
ceuticals Inc. (Sarawak, Malaysia).
2.2. Site-directed mutagenesis of HIV-1 RT
Mutant RT-enzymes containing the N137A, N137Q, N137Y,
N137K, N137T, N137E, N137D, N137H, N137S, P95A or P140A
mutation in both p66 and p51 subunits were derived from the RT se-
quence cloned in pKRT2His [14]. Site-directed mutagenesis was per-
formed using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene, Westburg, Leusden, The Netherlands), as described be-
fore [6]. The two synthetic oligonucleotide primers (Invitrogen Life
Technologies, Merelbeke, Belgium) used contained the desired muta-
tion at amino acid position 137, 140 or 95 of HIV-1 RT. The presence
of the desired mutation was conﬁrmed by sequencing the RT gene on
an ABI Prism 3100 sequencer (Applied Biosystems, Foster City, CA),
using the ABI Prism Big Dye Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems).
2.3. Construction of mutant recombinant HIV-1 reverse transcriptases
Recombinant HIV-1 RT enzymes were expressed from a two-
plasmid coexpression system as previously described [15]. The p66 sub-
unit of RT was expressed from pACYC66His and the p51 subunit
from pKRT51. To construct wild-type and mutated pACYC66His,
wild-type and mutated pKRT2His were digested with EcoRI and AviII
and the RT-containing fragments were ligated into pACYC184 di-
gested with EcoRI and ScaI. To construct wild-type and mutated
pKRT51, wild-type and mutated pKRT2His were digested with NcoI
and KpnI and the RT-containing fragment was ligated into pKRT51
digested with NcoI and KpnI.
2.4. Preparation of E. coli extracts
Expression of recombinant RT was performed as described previ-
ously [16]. LB medium (800 ml) containing 100 lg/ml ampicillin and
10 lg/ml tetracycline was inoculated with an overnight culture of E.
coli JM109 transformed with both plasmids of the coexpression system
and started at an OD600 of 0.1. The culture was grown at 37 C, in-
duced with 1 mM ﬁnal concentration of IPTG for expression of RT,
and after centrifugation the pellet was stored at 20 C. Later, the bac-terial cell pellet was resuspended in 15 ml lysis buﬀer (50 mMNa-phos-
phate buﬀer, 5 mM b-mercapto-EtOH, 0.9% glucose, 100 mM NaCl,
1 mM PMSF, 10 lg/ml pepstatin, 10 lg/ml leupeptin and 10% glyc-
erol) and passed through a SLM Aminco French Pressure Cell Press
(Beun de Ronde, La Abcoude, The Netherlands). The lysate was cen-
trifuged for 20 min at 17000g.2.5. Puriﬁcation of wild-type and mutant recombinant HIV-1 RT
The puriﬁcation of RT was performed as described previously [16].
Brieﬂy, the supernatant of the lysed bacterial cell culture was incubated
with Ni–NTA resin (Qiagen). After sedimentation of the Ni–NTA re-
sin with the bound (His)6-tagged proteins, a column was formed and
washed twice with sodium phosphate buﬀer containing 10 mM imidaz-
ole. Then, the RT was eluted from the column with sodium phosphate
buﬀer containing 125 mM imidazole. The imidazole-containing buﬀer
was exchanged by a Tris–HCl buﬀer and the eluate was concentrated
to 2 ml using Ultrafree-15 centrifugal ﬁltration devices (Millipore,
Brussels, Belgium). The (His)6-tagged RT was further puriﬁed to about
98% purity over a Hitrap Heparin column (Amersham Biosciences,
Roosendaal, The Netherlands). All fractions containing heterodimer
RT were pooled and stored in a 50% glycerol buﬀer at 20 C. Protein
concentrations in these stock solutions were determined using the Bio-
Rad Protein Assay (Bio-Rad, Nazareth Eke, Belgium) with bovine ser-
um albumin (BSA) as standard.2.6. Reverse transcriptase assay
For determination of the 50% inhibitory concentration (IC50) of the
test compounds against HIV-1 RT, the RNA-dependent DNA poly-
merase assay was performed as follows: the reaction mixture (50 ll)
contained 50 mM Tris–HCl (pH 7.8), 0.06% Triton X-100, 5 mM
DTT, 0.3 mM glutathione, 150 mM KCl, 5 mM MgCl2, 1.25 mg/ml
BSA, 0.5 mM EDTA, 0.1 mM template/primer poly(rC)Æoligo(dG)12–18
(Amersham Biosciences), a ﬁxed concentration of the labeled sub-
strate [8-3H]dGTP (1.6 lM, 1 lCi; speciﬁc activity, 12.6 Ci/mmol;
Amersham Biosciences), 5 ll of inhibitor solution [containing various
concentrations (10-fold dilutions) of the compounds], and 5 ll of the
RT preparations. In the case, where d4TTP (or PFA) were evaluated
for their inhibitory activity, 0.15 mM poly(rA)Æoligo(dT)12–18 was used
as the template/primer, and 1.6 lM [3H]dTTP as the radiolabeled sub-
strate. The reaction mixtures were incubated at 37 C for 30 min, at
which time 200 ll of yeast RNA (2 mg/ml) and 1 ml of trichloroacetic
acid (TCA) (5% in 20 mM Na4P2O7) were added. The solutions were
kept on ice for at least 30 min, after which the acid-insoluble material
was precipitated on Whatman GF/C glass-ﬁbre ﬁlters and washed with
20 ml TCA (5% in water) and 2 ml ethanol. The amount of incorpo-
rated radioactive substrate was analyzed in a liquid scintillation coun-
ter (Canberra Packard, Zellik, Belgium). The IC50 for each test
compound was determined as the compound concentration that inhib-
ited HIV-1 RT activity by 50%.2.7. Stability of wild-type and mutant heterodimer HIV-1 RTs in the
presence of diﬀerent urea concentrations
Denaturation curves were plotted by preincubation of RT with dif-
ferent concentrations of urea ranging from 0.0625 M up to 2.0 M for
10 min at 37 C in 50-ll reaction buﬀer as described above. The poly-
merase reaction was initiated by adding 1 ll [8-3H]dGTP (1 mCi/ml)
(Amersham Biosciences) as substrate. After incubating for 10 min at
37 C the reactions were terminated, precipitated, washed and ana-
lyzed as described above. Polymerase activity was determined as the
amount of nucleotide incorporated at each urea concentration relative
to the amount of nucleotide incorporation in the absence of denatur-
ant. The percentage polymerase activity was plotted versus the urea
concentration and the data were ﬁtted to a curve using the program
SigmaPlot Version 8.0 (SPSS Inc.) to determine the concentration of
urea at the midpoint of the denaturation curve.2.8. Three-dimensional structure visualization
The RT structure was visualized using the ViewerLite 5.0 software
(Accelrys Inc.; http://www.accelrys.com) and the X-ray coordinates
of a covalently trapped catalytic complex with a DNA template:primer
deposited in the Protein Data Bank (PDB, http://www.rcsb.org/PDB/)
with code 1RTD [17].
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3.1. RNA-dependent DNA polymerase activities of wild-type and
mutant N137X, P95A and P140A HIV-1 RTs
Nine recombinant mutant RTs were constructed by site-
directed mutagenesis at amino acid position 137, namely
N137A, N137Q, N137Y, N137K, N137T, N137E, N137S,
N137H and N137D. Also two mutant RT enzymes in which
the prolines at positions 95 and 140 were each replaced by
an alanine were made. The mutations were introduced in both
p66 and p51 subunits of the RT heterodimer, and all recombi-
nant mutant RTs were puriﬁed to P 98% homogeneity
through Ni–NTA- and heparin-containing aﬃnity columns.
Determination of the RNA-dependent DNA polymerase
(RDDP) activity of the mutant enzymes, using poly(rC)Æoli-
go(dG) as the template and [3H]dGTP as the radiolabeled
substrate, revealed that the mutant N137H RT retained 64%
of the catalytic activity (Fig. 1). The N137S, N137A and
N137Q RTs showed markedly compromised catalytic activity
(11–14% of that of wild-type RT) among the mutated
N137X RTs. Seriously impaired catalytic activities were noted
for the other ﬁve mutant N137X RTs. They only retained 3%
(for N137D) to less than 0.1% (for N137T and N137K) cata-
lytic activity. The proline to alanine mutations at positions
95 and 140 of HIV-1 RT also resulted in markedly decreased
RT activity (4% for mutant P95A RT enzyme and 0.3% for
mutant P140A RT enzyme) (Fig. 1).
3.2. Inhibitory activities of NNRTIs, PFA, ddGTP and d4TTP
against wild-type, N137X, P95A and P140A mutant HIV-1
RTs
The mutant N137X, P95A and P140A enzymes were evalu-
ated for their sensitivity to the inhibitory activity of a variety of
NNRTIs and ddGTP (Tables 1 and 2). Most of the mutant
N137X RTs kept full sensitivity to the NNRTIs tested. Only
the mutant N137K RT showed moderate resistance to (+)-
calanolide A (5-fold) but other NNRTIs retained their inhibi-
tory activity against this enzyme. Interestingly, all mutant
N137X RTs signiﬁcantly gained sensitivity towards the thio-
carboxanilide UC-781 (Tables 1 and 2). Also the P95A and
P140A RTs were 3- to 10-fold more sensitive to the inhibitory
eﬀect of UC-781. In contrast, substantial resistance toFig. 1. RNA-dependent DNA polymerase activity of mutant N137X, P95
independent experiments. S.D. is usually well-below 15% of the average acti(+)-calanolide A was observed for the mutant P95A RT en-
zyme (30-fold). Surprisingly, all mutant RT enzymes showed
less susceptibility and often even relatively high resistance
towards the nucleotide RT inhibitor ddGTP (up to 130-fold
for the mutant N137K RT), and, to a lesser extent, also to
d4TTP (Table 1). Also the pyrophosphate analog PFA showed
signiﬁcant resistance (up to 15-fold) depending the nature of
the mutation in RT.
3.3. Eﬀects of urea on wild-type and mutant N137A, N137E and
N137D RT activity
Wild-type and mutant N137A, N137E and N137D RTs were
exposed to a variety of urea concentrations and their catalytic
activity was measured under these experimental conditions
(Fig. 2). For the wild-type enzyme, the RT activity gradually
decreased in the presence of increasing concentrations of urea.
Half of the wild-type catalytic RT activity was retained at
0.75 M urea (i.e., the urea-IC50). When mutant N137 RTs
were exposed to diﬀerent concentrations of urea, the enzymes
showed increased sensitivity towards the denaturing eﬀect of
urea. Whereas the urea-IC50 shifted from 0.75 to 0.55 M for
the mutant N137A and N137D RTs, the urea-IC50 was further
decreased to 0.35 M for the mutant N137E RT enzyme.
3.4. Structural role of amino acids N137, P140 and P95 in HIV-
1 RT
The segment from I135 to P140 is part of the so-called b7–b8
loop that is present in both RT subunits (Fig. 3). In p66, this
loop is located on the top of the so-called ﬁnger domain of
RT and is exposed to the solvent, but in p51 the b7–b8 loop
has been identiﬁed as a binding energy ‘‘hot spot’’ for dimer-
ization [9,18]. This is in good agreement with the ﬁnding that
the b7–b8 loop is essential for the catalytic activity of the
p66 subunit [10,11]. Accordingly, whereas the side chain of
N137 in the p66 subunit is facing the solvent, in the p51 sub-
unit it is found lying on the peptide backbone of p66 in a
stretch comprising L92–G93–I94. It is worth mentioning that
the region encompassing amino acids 83–99 displays a diﬀerent
conformation in both subunits despite having identical compo-
sition. Thus, a short a-helix from P97 to G99 is present in the
larger (p66) subunit but it is absent in the smaller (p51) sub-
unit. Furthermore, the backbone of these two segments canA and P140A HIV-1 RT enzymes. Data are means of three to four
vity values.
Table 1
Inhibitory activity (IC50
b, lM) of test compounds against mutant N137X HIV-1 RTs
RTa mutation Nevirapine Delavirdine Efavirenz UC-781 GW420867X TSAO-m3T TSAO-T (+)-Calanolide A ddGTP d4TTP PFA
WT 1.1 ± 0.1 0.5 ± 0.3 0.011 ± 0.003 0.11 ± 0.09 0.011 ± 0.000 1.6 ± 0.6 1.6 ± 1.0 0.03 ± 0.01 0.05 ± 0.02 0.19 ± 0.02 3.4 ± 0.4
N137Y 0.61 ± 0.04 0.6 ± 0.2 0.008 ± 0.000 0.020 ± 0.005 0.008 ± 0.003 0.3 ± 0.1 0.41 ± 0.03 0.02 ± 0.01 1.2 ± 0.3 2.6 ± 0.3 39 ± 15
N137K 1.3 ± 0.3 0.8 ± 0.2 0.019 ± 0.004 0.04 ± 0.01 0.02 ± 0.01 3.3 ± 0.0 2.1 ± 0.8 0.155 ± 0.007 6.4 ± 1.1 3.3 ± 1.8 50 ± 0
N137T 1.1 ± 0.3 0.8 ± 0.3 0.011 ± 0.005 0.03 ± 0.01 0.03 ± 0.02 0.3 ± 0.2 0.7 ± 0.1 0.08 ± 0.01 2.2 ± 0.6 1.7 ± 0.0 15 ± 8
N137D 0.92 ± 0.02 0.3 ± 0.1 0.007 ± 0.001 0.020 ± 0.003 0.011 ± 0.003 1.2 ± 0.2 1.1 ± 0.7 0.07 ± 0.03 0.13 ± 0.07 1.6 ± 0.3 33 ± 7
N137A 1.0 ± 0.0 0.6 ± 0.5 0.009 ± 0.002 0.030 ± 0.001 0.010 ± 0.002 0.9 ± 0.4 1.8 ± 0.4 0.04 ± 0.03 0.2 ± 0.1 0.21 ± 0.05 28 ± 3
N137E 1.0 ± 0.1 0.7 ± 0.3 0.02 ± 0.01 0.032 ± 0.002 0.013 ± 0.001 1.7 ± 0.6 2 ± 1 0.09 ± 0.05 0.083 ± 0.002 0.04 ± 0.02 1.7 ± 0.5
N137Q 0.6 ± 0.2 0.4 ± 0.2 0.005 ± 0.001 0.027 ± 0.004 0.007 ± 0.000 0.8 ± 0.3 0.66 ± 0.00 0.07 ± 0.03 0.5 ± 0.1 0.24 ± 0.07 39 ± 15
N137H 0.5 ± 0.3 0.18 ± 0.04 0.015 ± 0.009 0.048 ± 0.001 0.011 ± 0.003 1.0 ± 0.4 1.1 ± 0.2 0.034 ± 0.000 0.70 ± 0.04 – –
N137S 0.36 ± 0.02 0.27 ± 0.01 0.005 ± 0.000 0.050 ± 0.001 0.021 ± 0.001 1.4 ± 0.4 1.0 ± 0.2 0.055 ± 0.007 0.39 ± 0.01 – –
P140A 0.8 ± 0.2 0.9 ± 0.1 0.009 ± 0.002 0.045 ± 0.009 0.010 ± 0.002 0.6 ± 0.4 1.07 ± 0.00 0.04 ± 0.01 1.3 ± 0.3 – –
P95A 1.0 ± 0.2 0.39 ± 0.00 0.008 ± 0.001 0.014 ± 0.001 0.012 ± 0.000 0.9 ± 0.7 0.9 ± 0.8 0.9 ± 0.1 1.4 ± 0.1 – –
Template/primer: 0.1 mM poly(rC)Æoligo(dG); substrate: 1.6 lM [3H]dGTP for all inhibitors except for d4TTP and PFA where 0.15 mM poly(rA)Æoligo(dT) was used as the template/primer and 1.6 lM
[3H]dTTP as the radiolabeled substrate.
Data are means for two to three independent experiments ± S.D.
aThe amino acid mutations are present in both p66 and p51 RT subunits.
b50% Inhibitory concentration, or compound concentration required to inhibit RT activity with 50%.
Table 2
Fold resistancea of mutant N137X, P140A and P95A HIV-1 RTs towards compounds tested in Table 1
RT mutation Nevirapine Delavirdine Efavirenz UC-781 GW420867X TSAO-m3T TSAO-T (+)-Calanolide A ddGTP d4TTP PFA
WT 1 1 1 1 1 1 1 1 1 1 1
N137Y 0.55 1.2 0.73 0.18 0.73 0.19 0.26 0.67 24 14 11
N137K 1.2 1.6 1.73 0.36 1.8 2.1 1.3 5.2 128 17 15
N137T 1 1.6 1 0.27 2.7 0.19 0.44 2.7 44 9 4.4
N137D 0.84 0.6 0.64 0.18 1 0.75 0.68 2.3 2.6 8.4 9.7
N137A 0.91 1.2 0.82 0.27 0.91 0.56 1.1 1.3 4 1.1 8.2
N137E 0.91 1.4 1.82 0.29 1.2 1.1 1.3 3 1.7 0.21 0.5
N137Q 0.55 0.8 0.45 0.25 0.64 0.5 0.41 2.3 10 1.3 11
N137H 0.45 0.36 1.36 0.44 1.0 0.63 0.69 1.1 14 – –
N137S 0.33 0.54 0.45 0.45 1.8 0.88 0.63 1.8 7.8 – –
P140A 0.73 0.82 0.82 0.41 0.91 0.38 0.67 1.3 26 – –
P95A 0.91 0.78 0.73 0.13 1.1 0.57 0.56 30 28 – –
aFold-resistance is expressed as the ratio of the IC50 of the test compounds against the mutant RT enzymes versus their IC50 against the wild-type RT enzyme.
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Fig. 3. Detail of the HIV-1 RT subunit interface showing as sticks the
side chains of N137 and P140 in the b7–b8 loop of p51 (pink ribbon)
and of P95 in the p66 subunit (cyan ribbon). Carbon atoms of the
DNA template:primer are colored grey whereas those of the incoming
nucleotide triphosphate are colored yellow. Residues Y181, Y188 and
W229 making up the NNRTI binding pocket and the catalytic D110,
D185 and D186 are shown as thick and thin sticks, respectively.
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G93, I94, P95, H96 and P97, which presents a highly invariant
amino acid region even in the presence of NNRTI (i.e., nevira-
pine, delavirdine and efavirenz) drug pressure (Ceccherini-
Silberstein et al., data not shown).4. Discussion
Because of its essential role in the HIV-1 replication cycle,
RT is an attractive target for anti-HIV therapies. All of the
current clinically used RT inhibitors are either competitive
(i.e., NRTIs and NtRTIs) or allosteric (i.e., NNRTIs) inhibi-
tors of HIV-1 RT. The catalytic activity of the RT enzyme is
only observed when it is in its (hetero)dimeric form [8]. The
NRTIs and NtRTIs interact with the substrate-binding site,
whereas the NNRTIs bind to an NNRTI-speciﬁc lipophilicpocket at a close distance from the NRTI-binding site. The
p66/p51 dimerization interface represents a potential novel tar-
get on HIV-1 RT that may lead to the development of new
classes of antiretrovirals [7,9,19–21]. Indeed, an important re-
gion for dimerization of the RT is an amino acid stretch (com-
prising P134 to P140), which forms the b7–b8 loop in the p51
subunit [18]. It has an essential role in maintaining the catalytic
activity of the p66 subunit [10]. When the highly conserved
N137 in this amino acid stretch was replaced by other amino
acid residues, a strong decrease in DNA polymerase activity
was noted. Thus, replacement by either the closely related Q
or by an A that would not be expected to give rise to steric hin-
drance at the dimer interface resulted in enzymes that retained
just about 10% of the activity of the wild-type counterpart.
However, substitutions involving bulkier (e.g., T or Y) or more
charged side chains (e.g., E, D and K) probably inﬂuence the
interaction of wild-type N137 with the carbonyl oxygen of
the main peptide chain of I94 in the p66 subunit in a more dra-
matic manner (catalytic activity between 3% and 0.02% of
wild-type RT).
The p51 subunit is involved in the critical step of loading the
p66 subunit onto the DNA template/primer [22], and struc-
tural evidence points to a tight association between the sub-
units. P95 in p66 and both N136 and N137 in p51 have been
shown to contribute to a large extent to the dimerization bind-
ing energy [18]. The binding of small molecule inhibitors like
the TSAO derivatives at this interface region can destabilize
the RT subunit interaction and inhibits the RT catalytic activ-
ity [23]. Mutations in these positions are likely to disrupt the
interface in such a way that the resulting conformation of
RT is not compatible with optimal catalytic activity. This fea-
ture has been observed under our experimental conditions.
Moreover, the increased sensitivity of the mutated N137 RTs
to the denaturing (inactivating) eﬀect of urea relative to wild-
type is in agreement with this hypothesis: a less tight interac-
tion between the p66 and p51 subunits in the mutant RT
enzymes decreases RT activity at lower urea concentrations
than happens with wild-type enzyme. The increased sensitivity
of the mutant enzymes to the denaturing (inactivating) eﬀect of
urea is due to an easier conversion of the mutant (heterodi-
meric) enzymes to their monomeric state, rather than to easier
unfolding of their secondary structure by urea. Indeed, Sluis-
Cremer et al. [24] and Mene´ndez-Arias et al. [12] have shown
that urea at concentrations less than 2 M (as is the case in
our experiments) results in a decreased catalytic activity of
the RT enzyme due to dissociation of the heterodimer to
monomers, and not to destruction (unfolding) of the second-
ary structure of the enzyme (which occurs at higher urea con-
centrations). Our observations are also in agreement with
earlier published results that focus on the importance of an in-
tact b7–b8 loop in the p51 subunit to retain eﬃcient catalytic
activity of the enzyme [10,11].
Thus, we can conclude that N137 in the b7–b8 loop of the
p51 subunit plays a crucial role in maintaining the catalytic
activity of heterodimeric RT by favoring an optimal confor-
mation of the p66 substrate active site.
Since p51 is crucial for supporting the binding of the tem-
plate/primer to the p66 subunit [22], disturbing the p66/p51
interface by a mutation at position N137 in p51 may also (indi-
rectly) hamper the binding eﬃciency of the substrates (dNTPs)
and could account for our observation that the N137 mutant
enzyme is markedly resistant to ddGTP and, to a lesser extent,
J. Auwerx et al. / FEBS Letters 579 (2005) 2294–2300 2299also to d4TTP and PFA. Such dramatic change in the sensitiv-
ity of HIV-1 RT to NRTIs and PFA upon mutations in the
neighbourhood of the NNRTI-binding pocket site has, to
the best of our knowledge, never been observed before. In fact,
we found a close inverse correlation between the catalytic eﬃ-
ciency of the mutant enzymes on the one hand, and their de-
gree of resistance to the inhibitory activity of the substrate
analogs ddGTP (Fig. 4) and d4TTP on the other hand
(r = 0.77 and 0.58, respectively). Indeed, if the substrate active
site has been compromised by the N137X mutations in p51, it
is not unlikely that also the eﬃciency of binding of ddGTP
(and other NRTIs such as d4TTP) to the active site is aﬀected.
The observed resistance of N137K and P95A mutants to-
wards (+)-calanolide A and not towards other NNRTIs can
be explained by the fact that (+)-calanolide A may interact
with RT in a manner that is mechanistically diﬀerent from
other NNRTIs, which non-competitively inhibit RT with re-
spect of substrate and template/primer. Indeed, (+)-calanolide
A has been reported to be at least partly competitive with re-
spect to dNTP binding [25] and thus may interact diﬀerently
with the mutant RTs. The observed hypersensitivity towards
the thiocarboxanilide UC-781 for the majority of HIV-1 RT
mutants is rather puzzling because UC-781 makes direct con-
tacts with K101, V106, Y181 and F227 of p66, but not with
the p51 subunit [26,27]. It is possible that mutations at the base
of the NNRTI binding pocket induce a perturbation of theseTable 3
Mutation proﬁle of the amino acid P95 and the amino acids in the b7–b8 l
NNRTI-treated patients (=1556 isolates)
Naı¨ve Wild-type
n % Mutation
0 0 P95
1 0.22 S1 P133
3 0.66 R1C2 S134
200 43.76 P1Q2K3M5L5R14V27T143 I135
0 0.0 N136
0 0.0 N137
21 4.6 R1K2G2A16 E138
10 2.2 V1M1A1R2I2P3 T139
1 0.22 L1 P140
n represents the number of patients with a mutation at a particular amino acid
mutation is indicated in subscript. The wild-type consensus amino acid is in
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Fig. 4. Inverse correlation between the catalytic DNA polymerase activity o
activity of the NRTI ddGTP. Poly(rC)Æoligo(dG) was used as the template pamino acids in the NNRTI pocket in such a way that the bind-
ing of UC-781 in RT becomes more optimized.
Evidence from clinical data supports the view that N137 is a
highly conserved amino acid in the HIV-1 RT because in non-
treated patients (n = 457) mutations at N137 have never been
observed and only 0.39% of NRTI/NNRTI-treated patients
(n = 1556) have mutations at this position (either N137S or
N137H) (Table 3). Also, in a cohort of 865 patients that were
NRTI-treated but NNRTI-naı¨ve, only two patients (0.23%)
contained the N137S mutation in the RT. It is probably no
co-incidence that the very few mutations that have been ob-
served in NRTI/NNRTI-exposed HIV-1-infected individuals
(four patients with N137S RT and two patients with N137H
RT out of 1556 patients) (Table 3) harbour the N137H and
N137S mutations that have the least impact on the catalytic
RT activity. Moreover, given the partial resistance of the mu-
tant N137S/H RTs to NRTIs (i.e., ddGTP), these mutations
can well be selected in the patients cohort by the NRTI pres-
sure rather than by the NNRTI pressure. These observations
perfectly ﬁt with our ﬁndings that most changes at amino acid
residue N137 have a dramatic eﬀect on the catalytic activity.
Thus, it is rather unlikely that single-mutant virus strains will
easily arise upon exposure of HIV-1 to drugs that are targeted
at this amino acid or the site (i.e. P95) on p66 where the side
chain of the N137 amino acid binds through two hydrogen
bonds.oop of HIV-1 RT from drug-naı¨ve patients (457 isolates) and NRTI/
Treated
Mutation % n
0.00 0
0.00 0
T1R1 0.13 2
T572V108L92M38R14K10A2 52.89 823
T12I2K1 0.96 15
S4H2 0.39 6
A79G22Q17K14T3S2D2R2 8.42 131
K19R18A13Q9M6I3S2V1P1 4.37 68
Q2T2 0.26 4
position. The individual number of patients with a speciﬁc amino acid
dicated in bold.
A
SQ
D
WT
0.5 1 1.5 2 2.5
activity
f the mutant N137X RT enzymes and their resistance to the inhibitory
rimer and [3H]dGTP as the radiolabeled substrate.
2300 J. Auwerx et al. / FEBS Letters 579 (2005) 2294–2300Because N137 is (i) highly conserved in HIV-1 RT, (ii) found
at the interface between p66 and p51, (iii) diﬃcult to mutate
without severe loss of RT activity and also because mutation
at position 137 does not result in marked resistance against
NNRTIs, we can conclude that N137 is a hot spot instrumen-
tal for RT p66/p51 dimerization and enzyme activity. This
makes N137 an interesting amino acid to be targeted in struc-
ture-based attempts to design novel potential RT dimerization
inhibitors. The same reasoning can be applied to the P95 resi-
due (in the p66 subunit) and the P140 residue (in the p51 sub-
unit) of RT. Drug design to test these hypotheses is currently
underway.
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